Inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease: event-free survival in INCREASE study open-label extension
S. Nathan (Falls Church, United States), R. Argula (Mount Pleasant, United States), S. Rajagopal (Durham, United States), S. Johri (Richmond, United States), D. De La Zerda (Miami, United States), D. Mcglothlin (San Francisco, United States), P. Smith (Durham, United States), C. Deng (Durham, United States), M. Miceli (Durham, United States), V. Tapson (Los Angeles, United States), A. Waxman (Boston, United States)
Source: International Congress 2022 – Novelties in pulmonary hypertension management
Session: Novelties in pulmonary hypertension management
Session type: Oral Presentation
Number: 2279
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Nathan (Falls Church, United States), R. Argula (Mount Pleasant, United States), S. Rajagopal (Durham, United States), S. Johri (Richmond, United States), D. De La Zerda (Miami, United States), D. Mcglothlin (San Francisco, United States), P. Smith (Durham, United States), C. Deng (Durham, United States), M. Miceli (Durham, United States), V. Tapson (Los Angeles, United States), A. Waxman (Boston, United States). Inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease: event-free survival in INCREASE study open-label extension. 2279
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|